GGrantIndex
← Leaderboards

Anuja Dokras-Jagasia

University Of Iowa

$4,413,751
Attributed
$4,413,751
Total exposure
11
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $606.1K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$4,413,751 · 11

By mechanism

R01$3,807,465 · 2
K08$294,030 · 1
R03$162,500 · 1
M01$81,756 · 6
R13$68,000 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Iowa

Same institution · by research overlap

Others in their field

Top investigators on “Woman

Research focus

WomanInsulin ResistancePolycystic Ovary SyndromeAffectMetabolicAndrogensReproductiveRisk FactorsHyperandrogenismPhenotypeCardiovascular DiseasesHirsutismDyslipidemiasNon-Insulin-Dependent Diabetes MellitusPharmaceutical PreparationsInsulinMetabolic SyndromeMorbidity - Disease RateGuidelinesMedicalInternationalPhysiciansRaceDiabetes Mellitus

Grant awards (27)

Resistant starch treatment of polycystic ovary syndrome: impact on cardiometabolic dysfunction and the gut microbiome$476,129
R01 · FY2025 · HL · contact PI
Androgen Excess Polycystic Ovary Syndrome Society Meeting$10,000
R13 · FY2025 · HD · contact PI
Resistant starch treatment of polycystic ovary syndrome: impact on cardiometabolic dysfunction and the gut microbiome$522,579
R01 · FY2024 · HL · contact PI
Androgen Excess Polycystic Ovary Syndrome Society Meeting$10,000
R13 · FY2024 · HD · contact PI
Use of novel 11-oxygenated androgens to improve diagnostic accuracy and therapeutics in polycystic ovary syndrome$81,250
R03 · FY2023 · HD · contact PI
Androgen Excess Polycystic Ovary Syndrome Society Meeting$10,000
R13 · FY2023 · HD · contact PI
Use of novel 11-oxygenated androgens to improve diagnostic accuracy and therapeutics in polycystic ovary syndrome$81,250
R03 · FY2022 · HD · contact PI
Androgen Excess Polycystic Ovary Syndrome Society Meeting$10,000
R13 · FY2022 · HD · contact PI
The COMET-PCOS trial - Comparing the effects of Oral Contraceptive Pills versus Metformin in the medical management of overweight/obese women with Polycystic Ovary Syndrome$506,874
R01 · FY2021 · HD · contact PI
Androgen Excess Polycystic Ovary Syndrome Society Meeting$10,000
R13 · FY2021 · HD · contact PI
The COMET-PCOS trial - Comparing the effects of Oral Contraceptive Pills versus Metformin in the medical management of overweight/obese women with Polycystic Ovary Syndrome$548,811
R01 · FY2020 · HD · contact PI
The COMET-PCOS trial - Comparing the effects of Oral Contraceptive Pills versus Metformin in the medical management of overweight/obese women with Polycystic Ovary Syndrome$568,991
R01 · FY2019 · HD · contact PI
Androgen Excess Polycystic Ovary Syndrome Society Meeting$6,000
R13 · FY2019 · HD · contact PI
The COMET-PCOS trial - Comparing the effects of Oral Contraceptive Pills versus Metformin in the medical management of overweight/obese women with Polycystic Ovary Syndrome$584,007
R01 · FY2018 · HD · contact PI
Androgen Excess Polycystic Ovary Syndrome Society Meeting$6,000
R13 · FY2018 · HD · contact PI
The COMET-PCOS trial - Comparing the effects of Oral Contraceptive Pills versus Metformin in the medical management of overweight/obese women with Polycystic Ovary Syndrome$600,074
R01 · FY2017 · HD · contact PI
Androgen Excess Polycystic Ovary Syndrome Society Meeting$6,000
R13 · FY2017 · HD · contact PI
DIAGNOSTIC MARKERS FOR EARLY DETECTION AND TREATMENT OF PRETERM PREGNANCIES$36,227
M01 · FY2007 · RR · contact PI
CARDIOVASCULAR RISK FACTORS IN WOMEN WITH PCOS$10,039
M01 · FY2007 · RR · contact PI
DIAGNOSTIC MARKERS FOR EARLY DETECTION AND TREATMENT OF PRETERM PREGNANCIES$8,934
M01 · FY2006 · RR · contact PI
POLYCYSTIC OVARY SYNDROME$2,978
M01 · FY2006 · RR · contact PI
CARDIOVASCULAR RISK FACTORS IN WOMEN WITH PCOS$1,655
M01 · FY2006 · RR · contact PI
POLYCYSTIC OVARY SYNDROME$8,093
M01 · FY2005 · RR
Regulation of maspin in placental development$98,010
K08 · FY2004 · HD
Polycystic Ovary Syndrome$13,830
M01 · FY2004 · RR
Regulation of maspin in placental development$98,010
K08 · FY2003 · HD
Regulation of maspin in placental development$98,010
K08 · FY2002 · HD